hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06281951 id: 2022/0271/HP briefTitle: Nebulized Fentanyl in Healthy Volunteers acronym: AEROfen overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2026-03-01 date: 2026-09-01 date: 2024-02-28 date: 2024-02-29 name: University Hospital, Rouen class: OTHER briefSummary: Pain constitutes the predominant motive prompting individuals to seek emergency medical attention, accounting for 80% of admissions to emergency departments. Presently, it is imperative to employ expeditious and efficacious analgesia-sedation methodologies, obviating the necessity for intravenous administration, while ensuring the secure delivery of pharmaceutical agents. The objective of this study is to assess the feasibility and comfort of nebulized intranasal or facial aerosol administration of Fentanyl through the implementation of a pharmacokinetic/pharmacodynamic (PK/PD) study conditions: Analgesia conditions: Emergencies studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: TREATMENT masking: NONE count: 20 type: ESTIMATED name: Fentanyl - Inhalation by facial nebulization name: Fentanyl - Nebulisation measure: Measurement of [F] bioavailability via facial nebulization and intranasal inhalation. measure: Measurement of maximum decrease in PUAL (pupillary under ambient light) between facial nebulization and intranasal inhalation. measure: Measurement of the difference between observed and predicted PUAL values by a PK/PD model. measure: Time required to achieve >30% decrease in PUAL compared to baseline. measure: Measurement of dose required to achieve >30% decrease in PUAL compared to baseline. measure: Measurement of administration comfort score using a visual analog scale ranging from 0 (maximum discomfort) to 10 (optimal comfort) (unitless). sex: ALL minimumAge: 18 Years maximumAge: 68 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University Hospital, Rouen city: Rouen zip: 76031 country: France lat: 49.44313 lon: 1.09932 hasResults: False
nctId: NCT06281938 id: 1617209 briefTitle: Machine Learning and 3D Image-based Modeling for Body Weight Estimation. overallStatus: NOT_YET_RECRUITING date: 2026-06 date: 2027-06 date: 2027-09 date: 2024-02-28 date: 2024-03-04 name: Florida Atlantic University class: OTHER briefSummary: The goal of this randomized controlled clinical trial is to \[learn about, test, compare etc.\] in critically ill or injured cohorts of patients presenting to the Emergency Department. The main question\[s\] it aims to answer are:
Researchers will compare the 3D camera group to those with standard care to see if the weight estimates are more accurate, to see if drug dosing is more accurate, and to compare the incidence of adverse events related to medications in each group. conditions: No Specific Conditions conditions: Weight, Body conditions: Drug Dose conditions: Weight-Estimation studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Intervention cohort and control cohort will be used primaryPurpose: OTHER masking: DOUBLE maskingDescription: Investigators and outcomes assessors will be blinded to the arm. Coded data will be used for masking. whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 320 type: ESTIMATED name: Weight estimation using 3D camera name: Standard care weight estimation measure: Weight estimation accuracy measure: Time to obtain weight estimate measure: Drug dosing accuracy measure: Correct dosing scalar used measure: Accuracy of in-bed scales sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06281925 id: 22-01363 briefTitle: Cryotherapy & Oxaliplatin overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-10-31 date: 2025-12-31 date: 2024-02-28 date: 2024-03-29 name: NYU Langone Health class: OTHER briefSummary: The primary objective of this study is to determine if cryotherapy is beneficial to patients with colon cancer who are receiving oxaliplatin in the prevention of developing chemotherapy induced peripheral neuropathy. conditions: Colon Cancer conditions: Peripheral Neuropathy studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 40 type: ESTIMATED name: Cryotherapy Gloves measure: Proportion of Participants with Peripheral Neuropathy at Visit 2 measure: Proportion of Participants with Peripheral Neuropathy at Visit 3 measure: Proportion of Participants with Peripheral Neuropathy at Visit 4 measure: Proportion of Participants with Peripheral Neuropathy at Visit 5 sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: NYU Langone Health city: Mineola state: New York zip: 11501 country: United States lat: 40.74927 lon: -73.64068 facility: NYU Langone Health city: New York state: New York zip: 10016 country: United States lat: 40.71427 lon: -74.00597 hasResults: False
nctId: NCT06281912 id: 4504/23 briefTitle: Impact of Anti PD-1 Therapy in Children, Adolescents and Young Adults (CAYA) Melanoma Patients acronym: MELCAYA overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2024-11 date: 2024-11 date: 2024-02-28 date: 2024-02-28 name: Azienda Ospedaliera di Perugia class: OTHER briefSummary: This is a retrospective observational cohort study, the primary objective is investigate the activity and efficacy of anti PD-1 antibodies in children, adolescents and young adult melanoma patients, with radically resected or metastatic disease conditions: Early Melanoma conditions: Advanced Melanoma studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 70 type: ESTIMATED measure: rate of objective response measure: adverse event incidence sex: ALL minimumAge: 12 Years maximumAge: 30 Years stdAges: CHILD stdAges: ADULT facility: Aix-Marseille Universite city: Marseille country: France lat: 43.29551 lon: 5.38958 facility: Institut Curie city: Paris country: France lat: 48.85341 lon: 2.3488 facility: Ospedale universitario della Charité city: Berlino country: Germany lat: 52.52437 lon: 13.41053 facility: German Cancer Research Center (Deutsches Krebsforschungszentrum (DKFZ) city: Heidelberg country: Germany lat: 49.40768 lon: 8.69079 facility: University Children's Hospital Tuebingen city: Tuebingen country: Germany lat: 48.52266 lon: 9.05222 facility: Universita Degli Studi Di Firenze city: Firenze country: Italy lat: 43.77925 lon: 11.24626 facility: Fondazione Irccs Istituto Nazionale Dei Tumori city: Milano country: Italy lat: 45.46427 lon: 9.18951 facility: Universita Cattolica Del Sacro Cuore city: Roma country: Italy lat: 41.89193 lon: 12.51133 facility: Princess Máxima Center for Pediatric Oncology (Prinses Máxima Centrum voor kinderoncologie) city: Utrecht country: Netherlands lat: 52.09083 lon: 5.12222 facility: Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy city: Warsaw country: Poland lat: 52.22977 lon: 21.01178 facility: Institut Catala D'Oncologia city: Barcellona country: Spain lat: 41.38879 lon: 2.15899 facility: Instituto de Investigaciones Biomédicas August Pi i Sunyer city: Barcellona country: Spain lat: 41.38879 lon: 2.15899 facility: Karolinska University Hospital city: Stockholm country: Sweden lat: 59.33258 lon: 18.0649 hasResults: False
nctId: NCT06281899 id: 01/2022 briefTitle: Effect of Low Protein Diet on Top of Dapagliflozin on Chronic Kidney Disease in Patients With Type 2 Diabetes Mellitus acronym: PRODAPA-CKD overallStatus: RECRUITING date: 2022-01-01 date: 2024-12-31 date: 2025-03-31 date: 2024-02-28 date: 2024-02-28 name: Anemia Working Group Romania class: OTHER name: Sf Ioan Emergency Clinical Hospital, Nephrology and Dialysis Department, Bucharest, Romania name: Dr Carol Davila Teaching Hospital of Nephrology, Nephrology Department, Bucharest, Romania name: Carol Davila University of Medicine and Pharmacy briefSummary: This is a prospective multicenter randomized controlled trial with a total duration of 36 months aiming to evaluate the effectiveness and the safety of low protein diet on top of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and renin-angiotensin-aldosterone inhibitors (RAASi) in reducing the progression of chronic kidney disease in patients with type 2 Diabetes Mellitus conditions: Chronic Kidney Diseases conditions: Type 2 Diabetes Mellitus studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 200 type: ESTIMATED name: Dapagliflozin 10 mg Tab name: Low protein diet measure: Time to the First Occurrence of Any of the Components of the Composite: ≥30% Sustained Decline in eGFR or Reaching ESRD or CV Death or Renal Death measure: Rate of decline in the estimated Glomerular Filtration Rate measure: Variation of albuminuria measure: Variation of HbA1C measure: Variation of serum cholesterol levels measure: Variation of serum bicarbonate levels measure: Variation of serum potassium levels measure: Variation of serum sodium levels measure: Variation of hemoglobin levels measure: Variation of hematocrit levels measure: All cause hospitalizations measure: Variation in body weight measure: Variation in BMI measure: Variation in handgrip strength measure: Variation in serum albumin levels measure: Variation in CRP levels measure: Changes in the quality of life measure: Compliance to the protein intake measure: Compliance to the energy intake measure: Compliance to carbohydrate intake sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Carol Davila University of Medicine and Pharmacy Bucharest status: RECRUITING city: Bucharest country: Romania name: Liliana Garneata, Assoc Prof role: CONTACT phone: +40722619358 email: lilianagarna@yahoo.com name: Elena Cuiban, MD role: CONTACT phone: +40748975315 email: elenacuiban@yahoo.com lat: 44.43225 lon: 26.10626 hasResults: False
nctId: NCT06281886 id: GASTO-10107 briefTitle: Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma overallStatus: RECRUITING date: 2023-12-01 date: 2026-12-01 date: 2026-12-01 date: 2024-02-28 date: 2024-02-28 name: Sun Yat-sen University class: OTHER briefSummary: This is an open-label, randomized, controlled phase II study evaluating induction immuno-chemotherapy and concurrent chemoradiotherapy with or without apatinib in unresectable, locally advanced esophageal squamous cell carcinoma conditions: Esophageal Squamous Cell Carcinoma conditions: Efficacy conditions: Toxicity studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 170 type: ESTIMATED name: Induction Immunotherapy-Toripalimab name: Induction Chemotherapy-Albumin-paclitaxel combined with cisplatin name: Radiotherapy name: Apatinib name: Capecitabine measure: Progression free survival rate measure: Overall survival measure: Objective response rate measure: Local-regional progression-free survival measure: Incidence of Treatment-related Adverse Events measure: Score of Quality of Life Questionnare-Core 30 (The European Organization for Reasearch and Treatment of Cancer) measure: Distant metastasis-free survival sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Sun yat-sen University Cancer Center status: RECRUITING city: Guangzhou state: Guangdong zip: 510060 country: China name: Bo Qiu, Professor role: CONTACT phone: +86-020-87343031 email: qiubo@sysucc.org.cn lat: 23.11667 lon: 113.25 hasResults: False
nctId: NCT06281873 id: 0645 briefTitle: Closure of Oroantral Fistula (OAF) Using Platelet Rich Fibrin With Middle Meatal Antrostomy overallStatus: COMPLETED date: 2023-03-27 date: 2023-09-01 date: 2024-02-07 date: 2024-02-28 date: 2024-02-28 name: Alexandria University class: OTHER briefSummary: the study evaluated the one stage endoscopic middle meatal antrostomy (EMMA) technique with the application of a platelet rich fibrin membrane (PRF) for Oroantral Fistula (OAF) closure and relief of maxillary sinusitis. conditions: Oroantral Fistula studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 9 type: ACTUAL name: closure by PRF membrane measure: Evaluation of the soft tissue wound's healing measure: Secondary radiographic outcomes, assessment of bone formation sex: ALL minimumAge: 20 Years maximumAge: 60 Years stdAges: ADULT facility: Faculty of Dentistry city: Alexandria zip: 562589 country: Egypt lat: 31.21564 lon: 29.95527 hasResults: False
nctId: NCT06281860 id: PITHAC id: 2023-00099 type: REGISTRY domain: BASEC briefTitle: Treatment Pleural Carcinosis of Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin Administration acronym: PITHAC overallStatus: RECRUITING date: 2023-11-24 date: 2025-12-01 date: 2026-02-01 date: 2024-02-28 date: 2024-02-28 name: Dr Jean Yannis PERENTES class: OTHER briefSummary: Within the context of pleural carcinosis, the present study is a dose escalation with determination of the maximum tolerated doses (MTD) of pressurized cisplatin administration associated to moderate hyperthermia in the pleura. This will be followed by an expansion phase at the recommended dose (RD). conditions: Mesothelioma, Malignant conditions: Carcinoma, Non-Small-Cell Lung conditions: Carcinoma Breast Stage IV conditions: Ovarian Cancer conditions: Esophageal Cancer conditions: Gastric Cancer studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: SEQUENTIAL interventionModelDescription: Open-label, non-randomised monocentric Phase I clinical trial study with cisplatin dose escalation administered by PITHAC. primaryPurpose: TREATMENT masking: NONE count: 39 type: ESTIMATED name: Cisplatine Teva® measure: Dose Escalation and Maximum Tolerated Dose determination (Part A): measure: Expansion phase (Part B): measure: Dose Escalation and MTD determination (Part A): measure: Expansion phase (Part B): measure: Dose Escalation and MTD determination (Part A):Exploratory outcomes measure: Expansion phase (Part B):Exploratory outcomes sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Centre Hospitalier Universitaire Vaudois status: RECRUITING city: Lausanne country: Switzerland name: Jean-Yannis PERENTES role: CONTACT name: Jean Yannis PERENTES role: PRINCIPAL_INVESTIGATOR lat: 46.516 lon: 6.63282 hasResults: False
nctId: NCT06281847 id: CCTx-001-AML-001 briefTitle: An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia acronym: RESOLVE AML001 overallStatus: NOT_YET_RECRUITING date: 2024-02 date: 2025-07 date: 2041-08 date: 2024-02-28 date: 2024-02-28 name: Advesya SAS class: INDUSTRY briefSummary: The purpose of this adaptive Phase 1/2 study is to evaluate the safety, tolerability, pharmacokinetics (PK), and antileukemic activity of CCTx-001 in adult patients with r/r Acute Myeloid Leukemia (AML). CCTx-001 targets IL-1RAP, which is specifically expressed in leukemic cells. In preclinical studies, IL-1RAP-targeted Chimeric antigen receptors (CARs) have demonstrated encouraging activity in both in vitro and in vivo experiments in AML models. Based on these promising preclinical results, it is expected that CCTx-001 could potentially alter the natural course of r/r AML and provide a potential novel treatment option. conditions: Acute Myeloid Leukemia, in Relapse conditions: Acute Myeloid Leukemia Refractory studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: The study comprises 4 periods:
* The long-term follow-up period will start after the Month 24 visit up to 15 years post CCTx-001 infusion. primaryPurpose: TREATMENT masking: NONE count: 143 type: ESTIMATED name: CCTx-001 measure: Phase 1: To evaluate the safety, tolerability, and to define the recommended phase 2 dose (RP2D) of CCTx-001 measure: Phase 2: To evaluate the clinical activity, as assessed by the composite complete response rate, in patients treated with CCTx-001 measure: Phase 2: To evaluate the clinical activity, as assessed by the complete remission rate, in patients treated with CCTx-001 measure: Phase 1: To evaluate the clinical activity, as assessed by the composite complete response rate, in patients treated with CCTx-001 measure: Phase 2: To assess the safety of CCTx-001 measure: Phase 2: To assess HRQoL for patients treated with CCTx-001 measure: Phase 2: To assess HRQoL for patients treated with CCTx-001 measure: Phase 1 & 2: To assess additional parameters of clinical activity in patients treated with CCTx-001 measure: Phase 1 & 2: To assess additional parameters of clinical activity in patients treated with CCTx-001 measure: Phase 1 & 2: To assess additional parameters of clinical activity in patients treated with CCTx-001 measure: Phase 1 & 2: To assess additional parameters of clinical activity in patients treated with CCTx-001 measure: Phase 1 & 2: To assess additional parameters of clinical activity in patients treated with CCTx-001 measure: Phase 1 & 2: To assess additional parameters of clinical activity in patients treated with CCTx-001 measure: Phase 1 & 2: To assess additional parameters of clinical activity in patients treated with CCTx-001 measure: Phase 1 & 2: To assess additional parameters of clinical activity in patients treated with CCTx-001 measure: Phase 1 & 2: To assess additional parameters of clinical activity in patients treated with CCTx-001 measure: Phase 1 & 2: To evaluate the overall safety and the tolerability of CCTx-001 sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Besançon Regional and University Hospital city: Besançon Cedex country: France name: Eric Deconinck role: CONTACT name: Eric Deconinck role: PRINCIPAL_INVESTIGATOR lat: 47.24878 lon: 6.01815 facility: Hospital Saint Louis city: Paris country: France name: Nicolas Boissel role: CONTACT name: Nicolas Boissel role: PRINCIPAL_INVESTIGATOR lat: 48.85341 lon: 2.3488 facility: Ludwig-Maximilians University of Munich city: Munich country: Germany name: Marion Subklewe role: CONTACT name: Marion Subklewe role: PRINCIPAL_INVESTIGATOR lat: 48.13743 lon: 11.57549 facility: University Hospital Ulm city: Ulm country: Germany name: Elisa Sala role: CONTACT name: Elisa Sala role: PRINCIPAL_INVESTIGATOR lat: 48.39841 lon: 9.99155 facility: Vall d'Hebron University Hospital city: Barcelona country: Spain name: Pere Barba role: CONTACT name: Pere Barba role: PRINCIPAL_INVESTIGATOR lat: 41.38879 lon: 2.15899 facility: Karolinska University Hospital city: Stockholm country: Sweden name: Stephan Mielke role: CONTACT name: Stephan Mielke role: PRINCIPAL_INVESTIGATOR lat: 59.33258 lon: 18.0649 hasResults: False
nctId: NCT06281834 id: 2024P000306 briefTitle: Dolutegravir Pharmacokinetics During Weekly Rifapentine/Isoniazid for TB Prevention overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2027-02 date: 2027-06 date: 2024-02-28 date: 2024-02-28 name: Brigham and Women's Hospital class: OTHER name: APIN Public Health Initiatives name: University of Cape Town briefSummary: Tuberculosis (TB) is the leading cause of death among children living with HIV, yet insufficient data are available on the pharmacokinetics of newer TB prevention strategies in children. Short-course TB prevention/latent TB infection (LTBI) treatment regimens increase completion rates but have not been adequately studied among children living with HIV. Our prospective, open-label PK study will examine and extend use of weekly rifapentine and isoniazid (3HP) among children receiving dolutegravir. This will address gaps in knowledge by examining two-way PK of short-course LTBI treatment in a vulnerable pediatric population. conditions: Pediatric HIV Infection conditions: Latent Tuberculosis studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Prospective single-arm, open-label, pharmacokinetic and safety study primaryPurpose: TREATMENT masking: NONE count: 25 type: ESTIMATED name: Rifapentine name: Dolutegravir measure: Dolutegravir AUC during weekly rifapentine/isoniazid measure: Rifapentine AUC measure: Proportion of participants experiencing severe (grade 3 or 4) clinical or laboratory adverse events sex: ALL minimumAge: 4 Weeks maximumAge: 11 Years stdAges: CHILD hasResults: False
nctId: NCT06281821 id: 4947 [Study 2] briefTitle: Mobile App-based Approach for Reducing Pain and Hazardous Drinking: a Pilot Study overallStatus: RECRUITING date: 2024-02-06 date: 2024-12-01 date: 2024-12-01 date: 2024-02-28 date: 2024-02-28 name: Boston University Charles River Campus class: OTHER name: National Institute on Alcohol Abuse and Alcoholism (NIAAA) briefSummary: Chronic pain and heavy drinking are common co-occurring conditions among patients presenting to primary care settings. Given their impact on functioning and medical outcomes, there would be considerable benefit to developing an accessible, easily utilized, integrative approach to reduce alcohol use and pain that can be readily incorporated into the health care settings. The objective of this study is to test a modified version of a smartphone-based intervention for reducing pain and alcohol use among individuals experiencing chronic pain who engage in heavy drinking. The primary goal is to test the feasibility and acceptability of implementing this intervention in a sample that includes participants from rural areas and providing initial data on the utility of the intervention. conditions: Alcohol Drinking conditions: Chronic Pain studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Compare an intervention to an assessment only control condition primaryPurpose: TREATMENT masking: SINGLE maskingDescription: Outcomes assessor at follow-up timepoint is masked to condition. Baseline assessment occurs prior to randomization whoMasked: OUTCOMES_ASSESSOR count: 32 type: ESTIMATED name: mhealth-pc measure: Pain (average weekly), Enjoyment of Life, General Activity (PEG) Scale measure: Time Line Follow-Back-30 Day Weekly Drinking measure: Time Line Follow-Back 30-Day Heavy Episodic Drinking measure: Perceptions of Treatment Questionnaire measure: Systems Usability Scale sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Boston University status: RECRUITING city: Boston state: Massachusetts zip: 02215 country: United States name: Maya Kratzer, BA role: CONTACT phone: 857-225-8843 lat: 42.35843 lon: -71.05977 hasResults: False
nctId: NCT06281808 id: R490 briefTitle: Photon Counting Detector CT Image Quality overallStatus: NOT_YET_RECRUITING date: 2024-02-28 date: 2026-09-01 date: 2026-12-31 date: 2024-02-28 date: 2024-02-28 name: Reto Sutter, MD class: OTHER briefSummary: This study aims to compare subjective image quality and diagnostic accuracy of a photon counting detector computed tomography (PCD-CT) scanner compared with an energy integrating detector (EID)-CT scanner as the reference standard. conditions: Diagnostic Imaging conditions: Tomography, X Ray Computed studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DIAGNOSTIC masking: NONE count: 200 type: ESTIMATED name: Photon Counting Detector CT measure: Image Quality PCD CT measure: Diagnostic Accuracy PCD CT sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False